Provectus Biopharmaceuticals, Inc. Overview
Pro stress-test →Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing a pipeline of immunotherapy medicines based on rose bengal sodium, a first-in-class synthetic small molecule from the halogenated xanthene family. The company's proprietary synthetic small molecule Rose Bengal Sodium is being systematically recognized and developed across oncology, dermatology, ophthalmology, and beyond.
Strategic Profile
Pro stress-test →Provectus Biopharmaceuticals remains a clinical-stage company with no product revenue. The company reported a net loss of $1.3 million for the three months ended March 31, 2026, compared with $1.16 million a year earlier. The company is relocating from its current offices at 800 S. Gay Street to Perkins Place, which is its planned new headquarters in 2026.
Competitive Landscape
Pro stress-test →Provectus competes in the clinical-stage immunotherapy and photodynamic therapy space against better-capitalized biotech companies. Competitors include larger immunotherapy developers and oncology-focused companies with established clinical programs and product revenue. The company's Rose Bengal Sodium platform is positioned as a first-in-class molecule, but faces significant competitive and funding pressures typical of pre-clinical-stage development programs.
Industry Context
Provectus Biopharmaceuticals, Inc. operates in Clinical-stage immunotherapy and photodynamic therapy.
Key facts
Founded: Unknown · Headquarters: Knoxville, US · Employees: Unknown · Revenue: $0 (clinical stage) · Market cap: N/A